RU2012137245A - Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций - Google Patents
Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций Download PDFInfo
- Publication number
- RU2012137245A RU2012137245A RU2012137245/15A RU2012137245A RU2012137245A RU 2012137245 A RU2012137245 A RU 2012137245A RU 2012137245/15 A RU2012137245/15 A RU 2012137245/15A RU 2012137245 A RU2012137245 A RU 2012137245A RU 2012137245 A RU2012137245 A RU 2012137245A
- Authority
- RU
- Russia
- Prior art keywords
- mutations
- inductor
- nonsense mutations
- nonsens
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
Abstract
1. Индуктор считывания для индукции считывания преждевременного стоп-кодона, образовавшегося вследствие нонсенс-мутаций, где индуктор считывания включает:соединение, имеющее структуру, отображаемую следующей структурной формулой (A):2. Лекарственное средство для лечения генетического заболевания, вызванного нонсенс-мутациями, где лекарственное средство включаетиндуктор считывания по п.1.3. Лекарственное средство по п.2, где генетическое заболевание, вызванное нонсенс-мутациями, представляет собой мышечную дистрофию.
Claims (3)
1. Индуктор считывания для индукции считывания преждевременного стоп-кодона, образовавшегося вследствие нонсенс-мутаций, где индуктор считывания включает:
соединение, имеющее структуру, отображаемую следующей структурной формулой (A):
2. Лекарственное средство для лечения генетического заболевания, вызванного нонсенс-мутациями, где лекарственное средство включает
индуктор считывания по п.1.
3. Лекарственное средство по п.2, где генетическое заболевание, вызванное нонсенс-мутациями, представляет собой мышечную дистрофию.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-021817 | 2010-02-03 | ||
| JP2010021817 | 2010-02-03 | ||
| PCT/JP2011/052263 WO2011096484A1 (ja) | 2010-02-03 | 2011-02-03 | リードスルー誘導剤、及びナンセンス変異型遺伝性疾患治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012137245A true RU2012137245A (ru) | 2014-03-10 |
| RU2571060C2 RU2571060C2 (ru) | 2015-12-20 |
Family
ID=44355477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012137245/15A RU2571060C2 (ru) | 2010-02-03 | 2011-02-03 | Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130005953A1 (ru) |
| EP (1) | EP2535051B1 (ru) |
| JP (1) | JP5705136B2 (ru) |
| KR (1) | KR20120123509A (ru) |
| CN (1) | CN102740860B (ru) |
| AU (1) | AU2011211744B2 (ru) |
| BR (1) | BR112012019515A2 (ru) |
| CA (1) | CA2788730A1 (ru) |
| IL (1) | IL221251A0 (ru) |
| MX (1) | MX2012009028A (ru) |
| RU (1) | RU2571060C2 (ru) |
| WO (1) | WO2011096484A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101703137B1 (ko) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN108014110A (zh) * | 2016-11-03 | 2018-05-11 | 武汉科技大学 | 灭瘟素的无义突变通读活性用途 |
| US20180315708A1 (en) * | 2017-05-01 | 2018-11-01 | Globalfoundries Inc. | Power rail and mol constructs for fdsoi |
| WO2019056581A1 (en) * | 2017-09-25 | 2019-03-28 | Antwave Intellectual Property Limited | SYSTEMS, APPARATUS AND METHODS FOR IMPROVING PERFORMANCE OF ANTENNA IN ELECTRONIC DEVICES |
| CA3175125A1 (en) | 2020-03-11 | 2021-09-16 | Biocomber Co., Ltd. | Single-stranded nucleic acid molecule for inducing -1 frameshift and composition |
| KR102517522B1 (ko) | 2020-12-28 | 2023-04-03 | 고려대학교 산학협력단 | 2-데옥시-스킬로이노사민을 포함하는 아미노사이클리톨 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488038A (en) * | 1992-11-27 | 1996-01-30 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Dibekacin derivatives and arbekacin derivatives active against resistant bacteria |
| EP1368039A4 (en) * | 2001-02-20 | 2006-03-29 | Uab Research Foundation | AMINOGLYCOSIDE TREATMENT FOR LYSOSOMAL STORAGE DISEASES |
| IL159311A0 (en) * | 2001-06-13 | 2004-06-01 | Remedies for diseases caused by nonsense mutation | |
| GB0600948D0 (en) | 2006-01-18 | 2006-02-22 | Univ Dundee | Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders |
| ES2689539T3 (es) * | 2006-04-03 | 2018-11-14 | Technion Research & Development Foundation Ltd. | Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos |
| CN1843330A (zh) * | 2006-05-24 | 2006-10-11 | 山东蓝金生物工程有限公司 | 一种含氨基糖苷类抗菌素的缓释剂及其应用 |
| RU2316590C1 (ru) * | 2006-06-16 | 2008-02-10 | Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pE-His8-TrxL-Ar2, КОДИРУЮЩАЯ ГИБРИДНЫЙ БЕЛОК, СОДЕРЖАЩИЙ АНТИМИКРОБНЫЙ ПЕПТИД АРЕНИЦИН МОРСКОГО КОЛЬЧАТОГО ЧЕРВЯ Arenicola marina, И ШТАММ Escherichia coli BL21(DE3)/pE-His8-TrxL-Ar2 - ПРОДУЦЕНТ ГИБРИДНОГО БЕЛКА, СОДЕРЖАЩЕГО АРЕНИЦИН |
| US20100093867A1 (en) * | 2006-07-05 | 2010-04-15 | Ryoichi Matsuda | Method Of Treating Genetic Disease Caused By Nonsense Mutation |
| US20100069455A1 (en) | 2006-08-21 | 2010-03-18 | Next21 K.K. | Bone model, bone filler and process for producing bone filler |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| JP5061345B2 (ja) * | 2006-09-26 | 2012-10-31 | 国立大学法人山口大学 | 薬剤耐性病原性微生物の薬剤感受性増強方法、および高度薬剤耐性菌の出現予防方法 |
| JP2008161075A (ja) * | 2006-12-27 | 2008-07-17 | Shizuoka Prefecture | タカアシガニ幼体の飼育方法及びその方法により飼育されたタカアシガニ幼体 |
| AR068332A1 (es) * | 2007-08-03 | 2009-11-11 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
| JP2009095436A (ja) * | 2007-10-16 | 2009-05-07 | Toray Ind Inc | 血液製剤浄化用材料および該材料を用いた浄化方法および浄化物 |
| JP5059045B2 (ja) * | 2008-03-28 | 2012-10-24 | 三井造船株式会社 | βラクタム系抗生物質含有水の処理方法 |
-
2011
- 2011-02-03 KR KR1020127022832A patent/KR20120123509A/ko not_active Application Discontinuation
- 2011-02-03 MX MX2012009028A patent/MX2012009028A/es not_active Application Discontinuation
- 2011-02-03 CA CA2788730A patent/CA2788730A1/en not_active Abandoned
- 2011-02-03 BR BR112012019515-8A patent/BR112012019515A2/pt not_active IP Right Cessation
- 2011-02-03 CN CN201180008253.8A patent/CN102740860B/zh not_active Expired - Fee Related
- 2011-02-03 AU AU2011211744A patent/AU2011211744B2/en not_active Ceased
- 2011-02-03 WO PCT/JP2011/052263 patent/WO2011096484A1/ja active Application Filing
- 2011-02-03 JP JP2011552822A patent/JP5705136B2/ja not_active Expired - Fee Related
- 2011-02-03 RU RU2012137245/15A patent/RU2571060C2/ru not_active IP Right Cessation
- 2011-02-03 EP EP11739832.1A patent/EP2535051B1/en not_active Not-in-force
-
2012
- 2012-08-01 IL IL221251A patent/IL221251A0/en unknown
- 2012-08-01 US US13/563,872 patent/US20130005953A1/en not_active Abandoned
-
2014
- 2014-09-15 US US14/486,321 patent/US9358246B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102740860B (zh) | 2014-11-19 |
| CA2788730A1 (en) | 2011-08-11 |
| IL221251A0 (en) | 2012-10-31 |
| CN102740860A (zh) | 2012-10-17 |
| AU2011211744B2 (en) | 2015-06-18 |
| JP5705136B2 (ja) | 2015-04-22 |
| AU2011211744A1 (en) | 2012-08-23 |
| US20130005953A1 (en) | 2013-01-03 |
| JPWO2011096484A1 (ja) | 2013-06-13 |
| RU2571060C2 (ru) | 2015-12-20 |
| KR20120123509A (ko) | 2012-11-08 |
| US20150005249A1 (en) | 2015-01-01 |
| EP2535051B1 (en) | 2016-04-20 |
| EP2535051A1 (en) | 2012-12-19 |
| MX2012009028A (es) | 2012-10-15 |
| WO2011096484A1 (ja) | 2011-08-11 |
| BR112012019515A2 (pt) | 2018-03-13 |
| US9358246B2 (en) | 2016-06-07 |
| EP2535051A4 (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012137245A (ru) | Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций | |
| EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| JP2011102304A5 (ru) | ||
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2013500986A5 (ru) | ||
| EA201270492A1 (ru) | Соединения для лечения дислипидемии и связанных с ней заболеваний | |
| EA201300558A1 (ru) | Соединения и способы для купирования боли | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| EA201590697A1 (ru) | Производные кетамина | |
| RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника | |
| EA201071006A1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| RU2009147456A (ru) | Лекарственное средство, содержащее производное карбостирила и донепезил, для лечения болезни альцгеймера | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2015516419A5 (ru) | ||
| EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
| EA201370230A1 (ru) | Новые ингибиторы rock | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160204 |